thermo fisher scientific inc. - TMO

TMO

Close Chg Chg %
392.56 5.33 1.36%

Closed Market

397.89

+5.33 (1.36%)

Volume: 3.76M

Last Updated:

Jun 20, 2025, 3:59 PM EDT

Company Overview: thermo fisher scientific inc. - TMO

TMO Key Data

Open

$393.92

Day Range

390.50 - 397.90

52 Week Range

385.46 - 627.86

Market Cap

$148.19B

Shares Outstanding

377.49M

Public Float

376.78M

Beta

0.78

Rev. Per Employee

N/A

P/E Ratio

23.04

EPS

$17.10

Yield

40.76%

Dividend

$0.43

EX-DIVIDEND DATE

Jun 13, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

2.50M

 

TMO Performance

1 Week
 
-2.53%
 
1 Month
 
-0.28%
 
3 Months
 
-24.18%
 
1 Year
 
-30.47%
 
5 Years
 
11.29%
 

TMO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About thermo fisher scientific inc. - TMO

Thermo Fisher Scientific, Inc. engages in serving the science community. Its mission is to enable customers to make the world healthier, cleaner and safer. The company serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Its global team delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increase its depth of capabilities across its broad portfolio of innovative products and services and leverage extensive global channels to address its customers’ needs. The firm do this through organic investments in research and development, capacity and capabilities and through acquisitions. Its goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

TMO At a Glance

Thermo Fisher Scientific, Inc.
168 Third Avenue
Waltham, Massachusetts 02451
Phone 1-781-622-1000 Revenue 42.88B
Industry Medical Specialties Net Income 6.34B
Sector Health Technology 2024 Sales Growth 0.051%
Fiscal Year-end 12 / 2025 Employees 125,000
View SEC Filings

TMO Valuation

P/E Current 23.036
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 31.452
Price to Sales Ratio 4.647
Price to Book Ratio 3.995
Price to Cash Flow Ratio 22.989
Enterprise Value to EBITDA 21.033
Enterprise Value to Sales 5.283
Total Debt to Enterprise Value 0.145

TMO Efficiency

Revenue/Employee 343,032.00
Income Per Employee 50,680.00
Receivables Turnover 4.454
Total Asset Turnover 0.437

TMO Liquidity

Current Ratio 1.66
Quick Ratio 1.287
Cash Ratio 0.419

TMO Profitability

Gross Margin 41.344
Operating Margin 17.869
Pretax Margin 16.411
Net Margin 14.774
Return on Assets 6.463
Return on Equity 13.154
Return on Total Capital 7.692
Return on Invested Capital 7.96

TMO Capital Structure

Total Debt to Total Equity 66.10
Total Debt to Total Capital 39.795
Total Debt to Total Assets 33.677
Long-Term Debt to Equity 61.108
Long-Term Debt to Total Capital 36.79
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Thermo Fisher Scientific Inc. - TMO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
39.21B 44.91B 42.86B 42.88B
Sales Growth
+21.71% +14.55% -4.58% +0.05%
Cost of Goods Sold (COGS) incl D&A
19.58B 25.90B 25.66B 25.15B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.59B 3.38B 3.41B 3.11B
Depreciation
831.00M 986.00M 1.07B 1.16B
Amortization of Intangibles
1.76B 2.40B 2.34B 1.95B
COGS Growth
+20.91% +32.32% -0.93% -2.00%
Gross Income
19.63B 19.01B 17.19B 17.73B
Gross Income Growth
+22.51% -3.17% -9.56% +3.11%
Gross Profit Margin
+50.07% +42.33% +40.12% +41.34%
2021 2022 2023 2024 5-year trend
SG&A Expense
9.32B 10.49B 9.75B 10.07B
Research & Development
1.41B 1.47B 1.34B 1.39B
Other SG&A
7.91B 9.02B 8.41B 8.68B
SGA Growth
+15.90% +12.56% -7.04% +3.26%
Other Operating Expense
- - - -
-
Unusual Expense
865.00M 131.00M 496.00M 73.00M
EBIT after Unusual Expense
9.45B 8.39B 6.95B 7.59B
Non Operating Income/Expense
(76.00M) 167.00M 839.00M 1.10B
Non-Operating Interest Income
43.00M 272.00M 879.00M 1.08B
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
536.00M 726.00M 1.49B 1.65B
Interest Expense Growth
-3.07% +35.45% +105.37% +10.93%
Gross Interest Expense
536.00M 726.00M 1.49B 1.65B
Interest Capitalized
- - - -
-
Pretax Income
8.84B 7.83B 6.30B 7.04B
Pretax Income Growth
+22.37% -11.38% -19.62% +11.73%
Pretax Margin
+22.55% +17.44% +14.70% +16.41%
Income Tax
1.11B 703.00M 284.00M 657.00M
Income Tax - Current - Domestic
606.00M 1.07B 378.00M 691.00M
Income Tax - Current - Foreign
1.15B 633.00M 1.21B 1.18B
Income Tax - Deferred - Domestic
(246.00M) (683.00M) (653.00M) (1.14B)
Income Tax - Deferred - Foreign
(399.00M) (314.00M) (647.00M) (72.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.73B 6.96B 5.96B 6.34B
Minority Interest Expense
3.00M 10.00M (40.00M) 3.00M
Net Income
7.72B 6.95B 6.00B 6.33B
Net Income Growth
+21.18% -10.03% -13.74% +5.67%
Net Margin Growth
+19.70% +15.47% +13.99% +14.77%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
7.72B 6.95B 6.00B 6.33B
Preferred Dividends
- - - -
-
Net Income Available to Common
7.72B 6.95B 6.00B 6.33B
EPS (Basic)
19.6066 17.7296 15.5311 16.5838
EPS (Basic) Growth
+21.79% -9.57% -12.40% +6.78%
Basic Shares Outstanding
394.00M 392.00M 386.00M 382.00M
EPS (Diluted)
19.4584 17.6396 15.451 16.5405
EPS (Diluted) Growth
+21.79% -9.35% -12.41% +7.05%
Diluted Shares Outstanding
397.00M 394.00M 388.00M 383.00M
EBITDA
12.91B 11.91B 10.85B 10.77B
EBITDA Growth
+25.94% -7.78% -8.85% -0.76%
EBITDA Margin
+32.92% +26.51% +25.32% +25.12%

Snapshot

Average Recommendation BUY Average Target Price 559.60
Number of Ratings 31 Current Quarters Estimate 5.231
FY Report Date 06 / 2025 Current Year's Estimate 22.322
Last Quarter’s Earnings 5.15 Median PE on CY Estimate N/A
Year Ago Earnings 21.86 Next Fiscal Year Estimate 24.683
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 22 27 27
Mean Estimate 5.23 5.52 22.32 24.68
High Estimates 5.43 5.74 22.70 26.00
Low Estimate 5.18 5.27 22.00 23.50
Coefficient of Variance 0.93 2.02 0.69 2.24

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 21 22 20
OVERWEIGHT 5 5 6
HOLD 5 5 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Thermo Fisher Scientific Inc. - TMO

Date Name Shares Transaction Value
May 2, 2025 Gianluca Pettiti Executive Vice President 23,167 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $429.93 per share 9,960,188.31
Apr 2, 2025 Karen S. Lynch Director 28 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Scott M. Sperling Director 17,235 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Ingrid Freire Director 2,401 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Jennifer M. Johnson Director 398 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 R. Alexandra Keith Director 1,007 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Michael A. Boxer SVP and General Counsel 10,816 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $532.52 per share 5,759,736.32
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 123,174 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $253.99 per share 31,284,964.26
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,174 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $524.22 per share 60,376,514.28
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 116,419 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $523.29 per share 60,920,898.51
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 119,024 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $518.62 per share 61,728,226.88
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 120,724 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $517.39 per share 62,461,390.36
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $515.59 per share 63,197,928.66
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,974 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $514 per share 63,208,636.00
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,274 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $523.01 per share 60,289,454.74
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,576 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $521.52 per share 60,275,195.52
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 116,979 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $517.87 per share 60,579,914.73
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 118,597 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $516.72 per share 61,281,441.84
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 120,395 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $515.89 per share 62,110,576.55
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,283 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $514.58 per share 62,924,386.14

Thermo Fisher Scientific Inc. in the News